Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROPHENE 65 vs ALFENTA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Propoxyphene is a weak opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering perception of pain. It also has local anesthetic and moderate antitussive effects.
μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.
Relief of mild to moderate pain,FDA-approved for pain management (withdrawn due to cardiac toxicity)
Induction and maintenance of anesthesia,Analgesic supplement during surgical procedures,Intravenous use for monitored anesthesia care (MAC)
Propoxyphene napsylate 100 mg orally every 4 hours as needed for pain; maximum 600 mg/day.
Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.
Terminal elimination half-life of propoxyphene: 6-12 hours (mean ~8 hours); norpropoxyphene half-life: 22-36 hours, leading to accumulation with chronic dosing. Clinical context: prolonged half-life in elderly and hepatic impairment increases risk of toxicity.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours); prolonged in hepatic impairment.
Hepatic via CYP3A4 and CYP2D6 to norpropoxyphene (active metabolite with longer half-life). Minor metabolism via N-demethylation and glucuronidation.
Hepatic via CYP3A4 to inactive metabolites; major metabolite is desmethylalfentanil (inactive).
Renal elimination of unchanged drug and metabolites: propoxyphene and its major metabolite norpropoxyphene account for ~20-30% as unchanged drug in urine; remainder as conjugated metabolites. Biliary/fecal elimination accounts for <10%.
Primarily renal (urinary) elimination as metabolites; approximately 80% recovered in urine, 20% in feces.
Propoxyphene: ~78% bound to albumin; norpropoxyphene: ~95% bound to albumin.
Approximately 92% bound, primarily to alpha-1 acid glycoprotein and albumin.
Volume of distribution: 16-20 L/kg (suggesting extensive tissue binding). Clinical meaning: high Vd indicates wide distribution into tissues, contributing to long half-life and potential for accumulation.
0.5–1.0 L/kg; reflects moderate tissue distribution; higher Vd in neonates and elderly.
Oral: approximately 30-70% (first-pass metabolism). Other routes: not formulated for parenteral use.
Intravenous: 100%; intramuscular: approximately 90%; intrathecal: approximately 10% (due to systemic absorption following spinal administration).
Cr Cl < 30 m L/min: Avoid use due to accumulation of toxic metabolite norpropoxyphene. Cr Cl 30-50 m L/min: Reduce dose to 50 mg every 6 hours.
No specific dose adjustment is recommended for renal impairment; however, alfentanil is primarily metabolized in the liver and its pharmacokinetics are not significantly altered in renal failure.
Child-Pugh Class C: Contraindicated. Child-Pugh Class B: Avoid use or reduce dose by 50% with close monitoring.
In hepatic impairment (Child-Pugh class A, B, C): Reduce dose by 50% and titrate carefully due to prolonged elimination half-life. Consider lower initial doses and extended dosing intervals.
Not recommended for use in pediatric patients due to risk of respiratory depression and lack of established safety.
Children (1-12 years): Induction of anesthesia: 10-20 mcg/kg IV; maintenance: 5-10 mcg/kg IV or infusion 0.5-1 mcg/kg/min. For neonates and infants: Dose individualization required; titrate to effect.
Initiate at lowest dose (e.g., 50 mg every 6 hours) and titrate cautiously; avoid in patients with renal impairment or concomitant CNS depressants.
Elderly patients (>65 years): Reduce initial dose by 30-50% and administer slowly. Due to decreased clearance and increased sensitivity, lower infusion rates (e.g., 0.3-0.5 mcg/kg/min) may be needed.
WARNING: RISK OF CARDIAC TOXICITY AND OVERDOSE. Propoxyphene has been withdrawn from the US market due to risk of fatal cardiac arrhythmias (QT prolongation, torsade de pointes) even at therapeutic doses. Use with alcohol or other CNS depressants increases risk of respiratory depression and death.
Risk of respiratory depression, particularly in elderly or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Cardiac toxicity (QT prolongation, torsade de pointes); respiratory depression; CNS depression (additive with alcohol/other depressants); risk of abuse and dependence; renal or hepatic impairment; elderly patients; history of head injury; increased intracranial pressure; seizure disorders; acute abdominal conditions.
Respiratory depression; abuse potential; hypotension; bradycardia; muscle rigidity; serotonin syndrome with concurrent serotonergic drugs; adrenal insufficiency; risk of withdrawal with prolonged use.
Hypersensitivity to propoxyphene or opioid cross-sensitivity; known QT prolongation; concurrent use of MAO inhibitors; severe asthma or respiratory depression; obstructive airway disease; paralytic ileus; pregnancy and breastfeeding.
Hypersensitivity to alfentanil or any component; significant respiratory insufficiency; severe asthma; paralytic ileus; concurrent use of MAOIs (or within 14 days); acute or postoperative pain management in children (except for procedural sedation).
No specific food interactions; avoid excessive grapefruit juice as it may increase propoxyphene levels.
No known interactions with food. However, grapefruit juice may increase alfentanil serum concentrations due to CYP3A4 inhibition; avoid concurrent consumption.
FDA Pregnancy Category C. First trimester: Risk of neural tube defects, cardiovascular malformations, and cleft lip/palate based on prostaglandin synthesis inhibition. Second trimester: Limited data; potential for oligohydramnios. Third trimester: Premature closure of ductus arteriosus, fetal renal dysfunction with oligohydramnios, and neonatal pulmonary hypertension. Avoid in third trimester unless compelling need.
Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effects were observed at clinically relevant doses; however, high doses caused embryotoxicity and increased fetal mortality. Trimester-specific risks: First trimester - potential for minor malformations based on limited human data; second trimester - possible risk if used chronically; third trimester - prolonged use may lead to neonatal respiratory depression, withdrawal syndrome, or opioid dependence. Use only if benefits outweigh risks.
Excreted into breast milk in small amounts; M/P ratio approximately 0.7. Clinical studies show no adverse effects in infants at therapeutic maternal doses. However, due to potential for prostaglandin inhibition, caution is advised, especially in premature infants or those with platelet dysfunction. Consider monitoring infant for bruising, bleeding, or gastrointestinal effects.
Alfentanil is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.3. Estimated infant dose is <1% of maternal weight-adjusted dose, which is considered clinically insignificant. However, due to potential for neonatal opioid effects, caution is advised; monitor infant for drowsiness, respiratory depression, and feeding difficulties. Consider alternative analgesics with established safety profiles, such as acetaminophen or ibuprofen, for lactation.
No standard dose adjustment recommended for pregnancy. However, due to increased volume of distribution and renal clearance in pregnancy, lower plasma concentrations may occur. Clinical efficacy should guide therapy; dosing at the lower end of the recommended range (e.g., 325 mg every 4-6 hours) is prudent to minimize fetal exposure. Avoid high doses and chronic use in third trimester.
Pregnancy can alter pharmacokinetics of alfentanil. Increased plasma volume and distribution may require higher doses to achieve same effect, while decreased plasma protein binding may increase free fraction, potentiating effects. Alpha-1-acid glycoprotein levels change in pregnancy, affecting binding. In third trimester, clearance may be increased by up to 50% due to enhanced hepatic metabolism. Therefore, dose adjustments may be needed: consider starting at low dose and titrating to effect, with close monitoring. For intravenous administration, typical adult doses (5-20 μg/kg) may need adjustments; no standard pregnancy-specific dosing exists. Use the lowest effective dose for the shortest duration. In labor, avoid high doses prior to delivery due to risk of neonatal respiratory depression.
Propoxyphene is a weak opioid analgesic; avoid in patients with suicidal ideation or history of substance abuse due to risk of overdose and cardiac toxicity (QT prolongation). Use with caution in elderly and renal impairment; start at lower doses. Monitor for respiratory depression, especially when combined with CNS depressants.
Alfentanil is a potent, rapid-onset, short-acting opioid analgesic used primarily for induction and maintenance of anesthesia. Due to its high protein binding (90%) and rapid redistribution, it has a shorter duration of action than fentanyl, making it suitable for brief, painful procedures. It undergoes hepatic metabolism via CYP3A4, so concomitant use with CYP3A4 inhibitors like ketoconazole or erythromycin can prolong its effects. Use caution in elderly or hypovolemic patients due to increased risk of hypotension. Naloxone reverses respiratory depression. Alfentanil is 5-10 times less potent than fentanyl.
Take exactly as prescribed; do not increase dose or frequency.,Do not consume alcohol or other CNS depressants.,May cause dizziness or drowsiness; avoid driving until known effect.,Report any signs of allergic reaction or irregular heartbeat.,Do not stop abruptly; withdrawal symptoms may occur.
This medication is given only by a healthcare professional in a hospital or surgical setting.,You may feel drowsy, dizzy, or nauseated after receiving this drug.,Report any difficulty breathing or slow heart rate to your healthcare provider immediately.,Avoid alcohol and sedatives for 24 hours after administration, as they can increase side effects.,Do not drive or operate machinery until the effects have fully worn off.
No interactions on record
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROPHENE 65 vs ALFENTA, answered by our medical review team.
PROPHENE 65 is a Opioid Analgesic that works by Propoxyphene is a weak opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering perception of pain. It also has local anesthetic and moderate antitussive effects.. ALFENTA is a Opioid Analgesic that works by μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROPHENE 65 and ALFENTA depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROPHENE 65 is: Propoxyphene napsylate 100 mg orally every 4 hours as needed for pain; maximum 600 mg/day.. The standard adult dose of ALFENTA is: Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROPHENE 65 and ALFENTA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROPHENE 65 is classified as Category C. FDA Pregnancy Category C. First trimester: Risk of neural tube defects, cardiovascular malformations, and cleft lip/palate based on prostaglandin synthesis inhibition. Second trime. ALFENTA is classified as Category C. Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effect. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.